CompletedPhase 2NCT00093782
Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma
Studying Neuroendocrine carcinoma of pancreas
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Lillian SiuPrincess Margaret Hospital Phase 2 Consortium
- Intervention
- temsirolimus(drug)
- Enrollment
- 36 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2003 – 2011
Study locations (1)
- Princess Margaret Hospital Phase 2 Consortium, Toronto, Ontario, Canada
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00093782 on ClinicalTrials.govOther trials for Neuroendocrine carcinoma of pancreas
Additional recruiting or active studies for the same condition.